ZCM
CORT icon

Zebra Capital Management’s Corcept Therapeutics CORT Stock Holding History

Zebra Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,388
Closed -$225K – 124
2021
Q4 		$225K Sell
11,388
-4,198
-27% -$85.2K 0.36% 107
2021
Q3 		$307K Buy
+15,586
New +$326K 0.37% 101
2021
Q1 		– Sell
-46,989
Closed -$1.23M – 183
2020
Q4 		$1.23M Buy
46,989
+1,756
+4% +$37K 1.56% 4
2020
Q3 		$787K Buy
45,233
+11,490
+34% +$183K 1.22% 11
2020
Q2 		$568K Sell
33,743
-3,903
-10% -$54.8K 0.82% 28
2020
Q1 		$448K Sell
37,646
-962
-2% -$11.9K 0.72% 38
2019
Q4 		$467K Buy
38,608
+13,199
+52% +$184K 0.41% 82
2019
Q3 		$359K Sell
25,409
-13,798
-35% -$170K 0.39% 98
2019
Q2 		$437K Buy
39,207
+1,688
+4% +$18.8K 0.23% 132
2019
Q1 		$440K Buy
37,519
+5,230
+16% +$65K 0.23% 124
2018
Q4 		$431K Sell
32,289
-14,438
-31% -$191K 0.27% 153
2018
Q3 		$655K Sell
46,727
-10,452
-18% -$146K 0.3% 102
2018
Q2 		$899K Sell
57,179
-5,567
-9% -$96.8K 0.38% 109
2018
Q1 		$1.03M Buy
62,746
+8,587
+16% +$159K 0.37% 124
2017
Q4 		$978K Buy
54,159
+20,268
+60% +$367K 0.33% 144
2017
Q3 		$654K Buy
+33,891
New +$505K 0.21% 196

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zebra Capital Management's CORT Position: Q1 2022 in Review

Zebra Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2022, closing a stake of 11,388 shares — an estimated $225K sold.

Zebra Capital Management first reported a position in CORT in Q3 2017 and held it in 16 quarters. The position peaked at $1.23M in Q4 2020. 228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

  • Zebra Capital Management reported no remaining Corcept Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Zebra Capital Management sold 11,388 Corcept Therapeutics shares in Q1 2022, an estimated $225K.
  • Zebra Capital Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 16 quarters.
  • Zebra Capital Management's Corcept Therapeutics position peaked at $1.23M in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on Zebra Capital Management's 13F filing for Q1 2022, filed 16 May 2022.